Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter.
Apolipoprotein CIII (apoCIII) plays an important role in plasma triglyceride and remnant lipoprotein metabolism. Because hypertriglyceridemia is an independent risk factor in coronary artery disease and the presence in plasma of triglyceride-rich remnant lipoproteins is correlated with atherosclerosis, considerable research efforts have been focused on the identification of factors regulating apoCIII gene expression to decrease its production. Here we report that the orphan nuclear hormone receptor Rev-erbalpha regulates the human apoCIII gene promoter. In apoCIII expressing human hepatic HepG2 cells, transfection of Rev-erbalpha specifically repressed apoCIII gene promoter activity. We determined by deletion and site-directed mutagenesis experiments that Rev-erbalpha dependent repression is mainly due to an element present in the proximal promoter of the apoCIII gene. In contrast, we found no functional Rev-erbalpha response elements in the convergently transcribed human apoAI gene or the common regulatory enhancer. The identified Rev-erbalpha response element coincides with a RORalpha1 element, and in the present study we provide evidence that functional cross-talk between these orphan receptors modulates the apoCIII promoter. In vitro binding analysis showed that monomers of Rev-erbalpha bound this element but not another upstream RORalpha1 response element. In addition, we showed that the closely related nuclear orphan receptor RVR also specifically repressed the human apoCIII gene. These studies underscore a novel physiological role for members of the Rev-erb family of nuclear receptors in the regulation of genes involved in triglyceride metabolism and the pathogenesis of atherosclerosis.
Coste
Hervé
H
GlaxoSmithKline, 25 avenue du Québec, 91951 Les Ulis cedex, France. hjcc6201@gsk.com
Rodríguez
Joan C
JC
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000737:chemistry*; D002460:Cell Line; D004268:DNA-Binding Proteins; D006801:Humans; D008156:Luciferases / Q000378:metabolism; D008954:Models, Biological; D008957:Models, Genetic; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D056953:Nuclear Receptor Subfamily 1, Group D, Member 1; D010957:Plasmids / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011506:Proteins / Q000737:chemistry*; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid / Q000737:chemistry*; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D014162:Transfection; D014280:Triglycerides / Q000378:metabolism
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D004268:DNA-Binding Proteins; C064353:NR1D1 protein, human; D056953:Nuclear Receptor Subfamily 1, Group D, Member 1; D011506:Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid; D014280:Triglycerides; D008156:Luciferases